Welcome to our dedicated page for Citius Pharmaceuticals SEC filings (Ticker: CTXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Citius Pharmaceuticals (CTXR) means sifting through pages of trial protocols, FDA correspondence and financing notes. Those details hide inside dense 10-Ks, sudden 8-K material events and rapid-fire Form 4 insider trades—exactly where pivotal data on LYMPHIR, Mino-Lok and Halo-Lido first surface.
Stock Titan’s AI solves that problem. Our engine reads every Citius Pharmaceuticals quarterly earnings report 10-Q filing, flags shifts in R&D burn, and translates footnotes into plain English. Real-time alerts push Citius Pharmaceuticals Form 4 insider transactions the moment executives buy or sell, while concise summaries turn a 300-page Citius Pharmaceuticals annual report 10-K simplified into a five-minute brief. If you’re wondering how to interpret an 8-K describing Phase 3 results, our platform highlights trial endpoints and potential impact on approvals.
Here’s what investors routinely search for—and instantly find in one place:
- Citius Pharmaceuticals insider trading Form 4 transactions with contextual AI commentary.
- Citius Pharmaceuticals proxy statement executive compensation showing incentive alignment before data catalysts.
- Citius Pharmaceuticals 8-K material events explained—from FDA meeting minutes to merger updates.
- Citius Pharmaceuticals earnings report filing analysis that links cash runway to trial timelines.
- Guidance on understanding Citius Pharmaceuticals SEC documents with AI for faster due diligence.
Every filing—10-K, 10-Q, 8-K, S-3, or definitive proxy—lands on this page seconds after EDGAR posts, then is decoded by expert-trained AI. Save hours, spot catalyst-moving disclosures early, and follow Citius Pharmaceuticals executive stock transactions Form 4 in real time—all without plowing through biotech jargon.
Schedule 13D filing overview
On 06/30/2025 Atlantis Holding Corp. and Icon Energy Corp.’s Chairwoman & CEO, Ismini Panagiotidi, disclosed beneficial ownership of 7,685,546 common shares of Icon Energy (“ICON”), representing 77.9 % of the outstanding class.
The position consists of (i) 5,000 common shares held directly and (ii) 7,680,546 shares issuable upon conversion of 17,249 Series A Cumulative Convertible Perpetual Preferred Shares. The Series A shares are convertible, in whole (not in part), between 16 Jul 2025 and 15 Jul 2032 at the lower of US $240 or the 5-day VWAP immediately before notice.
The preferred stock was issued under a 11 Jun 2024 exchange whereby ICON acquired Maui Shipping Co.; a further 2,249 Series A shares were issued in-kind for dividends on 30 Jun 2025. Atlantis is incorporated in the Marshall Islands; Ms. Panagiotidi controls Atlantis and Pavimar Shipping, which manages vessels operated by ICON.
The filing states the stake is held for investment purposes and that there are currently no definitive plans for additional transactions affecting ICON’s capital, governance or operations, though regular discussions with management and directors occur.
Key investor takeaways: (1) ICON is effectively insider-controlled, limiting minority influence; (2) up to 7.68 million new shares could be issued after July 2025, creating potential dilution risk; (3) conversion price linkage to VWAP may mitigate extreme pricing but favors the holder if shares trade below US $240.
FAQ
What is the current stock price of Citius Pharmaceuticals (CTXR)?
What is the market cap of Citius Pharmaceuticals (CTXR)?
What is the primary focus of Citius Pharmaceuticals Inc.?
Which therapeutic areas are covered by their product pipeline?
What distinguishes LYMPHIR™ from other CTCL treatments?
How does Citius Pharmaceuticals ensure clinical excellence?
What role does innovation play in Citius Pharmaceuticals' business model?
How is the company positioned within the competitive landscape?
What are some key milestones achieved by the company?
What strategic initiatives support its product commercialization?
